Biotron Ltd - Company Profile
Powered by 
All the sales intelligence you need on Biotron Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Biotron Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Biotron Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Biotron Ltd (Biotron) is a clinical-stage biotechnology company. It specializes in developing antiviral drugs targeting viroporins, virus-encoded proteins crucial to viral pathogenesis. The company’s lead program, BIT225, has shown promise in treating HIV-1, with successful Phase 2 trials demonstrating its safety and efficacy in boosting immune responses and reducing viral markers. BIT225 showed potential in preclinical studies against COVID-19, and a Phase 2 trial is underway for SARS-CoV-2. The company is also developing therapies for Hepatitis B, Dengue, Zika, Influenza, and Ebola. Biotron is headquartered in Sydney, New South Wales, Australia.
Headquarters
Australia
Address
Level 2, 66 Hunter Street, Sydney, New South Wales, 2000
Website
www.biotron.com.au
Telephone
61 2 93003344
No of Employees
4
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BIT (ASX)
EPS
XYZ
Net Income (2024)
XYZ
90.7%
(2024 vs 2023)
Market Cap*
$4.0M
Net Profit Margin (2023)
XYZ
14.4%
(2024 vs 2023)
* As of and is in US$
Biotron Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| BIT225: HIV-1, SARS-CoV-2 and Hepatitis B |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In December, the company acquired Sedarex Limited, a biotech company. |
| 2016 | Contracts/Agreements | In February, Biotron Limited entered into a contract with ImQuest BioSciences, to test the activity of specific Biotron compounds against Zika virus. |
| 2010 | Official Trials/Tests | Successful conclusion of a Phase Ib/IIa clinical trial of Biotron’s lead drug, BIT225, in HCV infected subjects. This marked a major milestone for the Company. |
Competitor Comparison
| Key Parameters | Biotron Ltd | BLS Pharmaceuticals Ltd | Immuron Ltd | Chimeric Therapeutics Ltd | Kazia Therapeutics Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | Australia | Australia | Australia |
| City | Sydney | Sydney | Carlton | Carlton | Sydney |
| State/Province | New South Wales | New South Wales | Victoria | Victoria | New South Wales |
| No. of Employees | 4 | 16 | 7 | - | 12 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michelle Miller, Ph.D. | Chief Executive Officer; Managing Director | Executive Board | 2002 | - |
| Marcelo Mora | Secretary | Senior Management | 2025 | - |
| Paul Kasian | Director | Non Executive Board | 2025 | - |
| Michael Medway | Director | Non Executive Board | 2025 | - |
| Graeme Wald | Director | Non Executive Board | 2026 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer